JP2016534094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016534094A5 JP2016534094A5 JP2016530087A JP2016530087A JP2016534094A5 JP 2016534094 A5 JP2016534094 A5 JP 2016534094A5 JP 2016530087 A JP2016530087 A JP 2016530087A JP 2016530087 A JP2016530087 A JP 2016530087A JP 2016534094 A5 JP2016534094 A5 JP 2016534094A5
- Authority
- JP
- Japan
- Prior art keywords
- average diameter
- nanoscale construct
- nanoscale
- nucleic acid
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005557 antagonist Substances 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 230000003993 interaction Effects 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 108020004414 DNA Proteins 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 102000053602 DNA Human genes 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910017052 cobalt Inorganic materials 0.000 claims 1
- 239000010941 cobalt Substances 0.000 claims 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 239000011162 core material Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 229910052738 indium Inorganic materials 0.000 claims 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229910052759 nickel Inorganic materials 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- 150000004713 phosphodiesters Chemical class 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000004332 silver Substances 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361858584P | 2013-07-25 | 2013-07-25 | |
| US61/858,584 | 2013-07-25 | ||
| PCT/US2014/048294 WO2015013675A1 (en) | 2013-07-25 | 2014-07-25 | Spherical nucleic acid-based constructs as immunoregulatory agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016534094A JP2016534094A (ja) | 2016-11-04 |
| JP2016534094A5 true JP2016534094A5 (OSRAM) | 2017-09-07 |
Family
ID=51422128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016530087A Pending JP2016534094A (ja) | 2013-07-25 | 2014-07-25 | 免疫調節剤としての球状核酸に基づくコンストラクト |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20160194642A1 (OSRAM) |
| EP (1) | EP3024494A1 (OSRAM) |
| JP (1) | JP2016534094A (OSRAM) |
| KR (1) | KR20160045726A (OSRAM) |
| CN (1) | CN105658241A (OSRAM) |
| AU (1) | AU2014292928A1 (OSRAM) |
| CA (1) | CA2919273A1 (OSRAM) |
| WO (1) | WO2015013675A1 (OSRAM) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| US20130034599A1 (en) | 2010-01-19 | 2013-02-07 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
| KR20160042917A (ko) | 2013-07-25 | 2016-04-20 | 엑시큐어, 인크. | 예방 및 치료 용도를 위한 면역자극제로서의 구형 핵산-기재 구축물 |
| US10568898B2 (en) | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
| CN105939699B (zh) * | 2013-12-03 | 2020-10-02 | 西北大学 | 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途 |
| US10413565B2 (en) | 2014-04-30 | 2019-09-17 | Northwestern University | Nanostructures for modulating intercellular communication and uses thereof |
| US10434064B2 (en) | 2014-06-04 | 2019-10-08 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| WO2016057549A1 (en) | 2014-10-06 | 2016-04-14 | Aurasense Therapeutics, Llc | Anti-tnf compounds |
| EP3220895B1 (en) | 2014-11-21 | 2022-08-31 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| US10517924B2 (en) | 2014-11-24 | 2019-12-31 | Northwestern University | High density lipoprotein nanoparticles for inflammation |
| KR20170104550A (ko) * | 2015-01-14 | 2017-09-15 | 엑시큐어, 인크. | 코어 모티프를 갖는 핵산 나노구조 |
| WO2016134104A1 (en) * | 2015-02-18 | 2016-08-25 | Exicure, Inc. | Immuno-regulatory lipid containing spherical nucleic acids |
| WO2016149323A1 (en) * | 2015-03-16 | 2016-09-22 | Exicure, Inc. | Immunomodulatory spherical nucleic acids |
| US10078092B2 (en) | 2015-03-18 | 2018-09-18 | Northwestern University | Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules |
| US20180214376A1 (en) * | 2015-07-14 | 2018-08-02 | Exicure, Inc. | Spherical nucleic acid (sna)-mediated delivery of lipid-complexes to cells |
| US11866700B2 (en) | 2016-05-06 | 2024-01-09 | Exicure Operating Company | Liposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
| US20200291394A1 (en) * | 2017-05-17 | 2020-09-17 | Northwestern University | Conjugation of peptides to spherical nucleic acids (snas) using traceless linkers |
| KR20200028997A (ko) | 2017-07-13 | 2020-03-17 | 노오쓰웨스턴 유니버시티 | 올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법 |
| JP7023460B2 (ja) * | 2017-10-26 | 2022-02-22 | 国立大学法人 鹿児島大学 | Ｔｌｒリガンド固定化ナノ粒子 |
| US20210189397A1 (en) * | 2018-05-10 | 2021-06-24 | Northwestern University | Self-manageable abnormal scar treatment with spherical nucleic acid (sna) technology |
| WO2019246409A1 (en) * | 2018-06-20 | 2019-12-26 | Exicure, Inc. | Il-1 beta targeting spherical nucleic acids |
| US12319711B2 (en) | 2019-09-20 | 2025-06-03 | Northwestern University | Spherical nucleic acids with tailored and active protein coronae |
| US12378560B2 (en) | 2019-10-29 | 2025-08-05 | Northwestern University | Sequence multiplicity within spherical nucleic acids |
| US11951211B2 (en) * | 2020-01-31 | 2024-04-09 | Yale University | DNA brick-assisted liposome sorting |
| WO2024121814A1 (en) * | 2022-12-09 | 2024-06-13 | Takeda Pharmaceutical Company Limited | Modified immunomodulators |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5472881A (en) | 1992-11-12 | 1995-12-05 | University Of Utah Research Foundation | Thiol labeling of DNA for attachment to gold surfaces |
| US6750016B2 (en) | 1996-07-29 | 2004-06-15 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
| US6361944B1 (en) | 1996-07-29 | 2002-03-26 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
| AU4043497A (en) | 1996-07-29 | 1998-02-20 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US6506569B1 (en) | 1997-05-30 | 2003-01-14 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR10 |
| JP2003503699A (ja) | 1999-06-25 | 2003-01-28 | ナノスフェアー インコーポレイテッド | オリゴヌクレオチドが付着しているナノ粒子およびその利用法 |
| EP1294930B1 (en) | 2000-01-13 | 2011-03-30 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
| AU2001255203A1 (en) | 2000-03-28 | 2001-10-08 | Nanosphere Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
| AU2002239726A1 (en) | 2001-05-25 | 2002-12-09 | Northwestern University | Non-alloying core shell nanoparticles |
| AU2002364927A1 (en) | 2001-07-10 | 2003-06-30 | North Carolina State University | Nanoparticle delivery vehicle |
| WO2006138145A1 (en) | 2005-06-14 | 2006-12-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
| CA2691066C (en) | 2007-02-09 | 2018-07-31 | Northwestern University | Particles for detecting intracellular targets |
| EP2129803A4 (en) | 2007-02-27 | 2010-11-03 | Univ Northwestern | APPLICATION OF MOLECULES TO NANOPARTICLES |
| EP2160464B1 (en) | 2007-05-30 | 2014-05-21 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
| US20100035967A1 (en) * | 2008-07-28 | 2010-02-11 | Idera Pharmaceuticals, Inc. | Modulation of toll-like receptor 9 expression by antisense oligonucleotides |
| AU2009316286B2 (en) | 2008-11-24 | 2016-05-26 | Northwestern University | Polyvalent RNA-nanoparticle compositions |
| JP5801205B2 (ja) | 2009-01-08 | 2015-10-28 | ノースウェスタン ユニバーシティ | 多価オリゴヌクレオチド修飾ナノ粒子コンジュゲートによる細菌タンパク質産生の阻害 |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| US20100294952A1 (en) | 2009-01-15 | 2010-11-25 | Northwestern University | Controlled agent release and sequestration |
| WO2011017456A2 (en) | 2009-08-04 | 2011-02-10 | Northwestern University | Localized delivery of nanoparticles for therapeutic and diagnostic applications |
| US20120269730A1 (en) | 2009-08-07 | 2012-10-25 | Northwestern University | Intracellular Delivery of Contrast Agents with Functionalized Nanoparticles |
| US20110111974A1 (en) | 2009-10-23 | 2011-05-12 | Northwestern University | Short Duplex Probes for Enhanced Target Hybridization |
| DK2494075T3 (en) | 2009-10-30 | 2018-07-23 | Univ Northwestern | TABLE-MANAGED NANOCONJUGATES |
| US20130178610A1 (en) | 2009-12-24 | 2013-07-11 | Chad A. Mirkin | Oligonucleotide specific uptake of nanoconjugates |
| EP2399608B1 (en) * | 2010-03-05 | 2020-07-08 | Sebastian Fuchs | Immunomodulating nanoparticulate composition for use in inhalation therapy |
-
2014
- 2014-07-25 CN CN201480052513.5A patent/CN105658241A/zh active Pending
- 2014-07-25 KR KR1020167004851A patent/KR20160045726A/ko not_active Withdrawn
- 2014-07-25 WO PCT/US2014/048294 patent/WO2015013675A1/en not_active Ceased
- 2014-07-25 JP JP2016530087A patent/JP2016534094A/ja active Pending
- 2014-07-25 US US14/907,455 patent/US20160194642A1/en not_active Abandoned
- 2014-07-25 CA CA2919273A patent/CA2919273A1/en not_active Abandoned
- 2014-07-25 AU AU2014292928A patent/AU2014292928A1/en not_active Abandoned
- 2014-07-25 EP EP14756142.7A patent/EP3024494A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016534094A5 (OSRAM) | ||
| JP2016530879A5 (OSRAM) | ||
| Bates et al. | G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms | |
| JP6697384B2 (ja) | 予防的および治療的使用のための免疫刺激剤としての球状の核酸ベース構築物 | |
| JP2015516989A5 (OSRAM) | ||
| Donaldson et al. | The biologically effective dose in inhalation nanotoxicology | |
| US20160194642A1 (en) | Spherical nucleic acid-based constructs as immunoregulatory agents | |
| Li et al. | Improving the yield of mono-DNA-functionalized gold nanoparticles through dual steric hindrance | |
| JP2012029693A5 (OSRAM) | ||
| Gooding et al. | Oligonucleotide conjugates–Candidates for gene silencing therapeutics | |
| JP2019505485A5 (OSRAM) | ||
| Genchi et al. | Bioapplications of boron nitride nanotubes | |
| Mollah et al. | Overcoming therapy resistance and relapse in TNBC: Emerging technologies to target breast cancer-associated fibroblasts | |
| Zhan et al. | Improved tumor infiltration and immunomodulation for tumor therapy: a pathway based on tetrahedral framework nucleic acids coupled bacterial nanocells | |
| WO2008045576A3 (en) | Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases | |
| BR112014007501A2 (pt) | conjunto remoto de nanopartículas direcionadas usando ligantes de oligonucleotídeos complementares | |
| Jebali et al. | Hybridization of different antisense oligonucleotides on the surface of gold nanoparticles to silence zinc metalloproteinase gene after uptake by Leishmania major | |
| Cazac et al. | Morphological features of lymphatic microvessel density depending on stage of cervical neoplasia | |
| Dobson | Biomedical Applications of Magnetic Nanoparticles: Delivering Genes and Remote Control of Cells | |
| Abbas | Genetic Diversity and Population Structure of Chinese Misgurnus anguillicaudatus and Elopichthys bambusa in the Yangtze River Basin as Revealed by Molecular Markers | |
| Shah | Manipulation of Nano Rod Proteins: ToMV and MfpA for Bionanoscience | |
| Popescu et al. | Specifically targeted imaging using functionalized nanoparticles | |
| Mezzaroba et al. | DEVELOPMENT OF CHLORAMBUCIL/HYDROXYCHLOROQUINE-LOADED ANTI-CD20 NANOPARTICLES FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA: IN VITRO MODEL | |
| FENG | The Evolving Art of Paper Making over Millennia | |
| Sergeevna et al. | Evaluation of the EHF-therapeutic influence on mice's prostate state with experimental chronic prostatitis |